Three Compliance Risks in International Medical Device Launches

Below are three specific pain points medical device manufacturers face today, and how working with the right medical device translation partner addresses each one.

Getting a medical device to market takes years of engineering, clinical testing, and regulatory work. The last thing a manufacturer needs is a documentation bottleneck delaying launch or triggering a compliance deficiency. Yet for many companies, that's exactly what happens, especially when expanding into international markets.

1. Inaccuracies Delay Certifications

The EU Medical Device Regulation has fundamentally changed what manufacturers must submit to Notified Bodies. Technical files are larger, clinical evidence requirements are stricter, and the documentation burden across the product lifecycle has grown substantially. Notified Bodies are already stretched thin, with average MDR certification timelines running 13 to 18 months for standard devices and longer for complex ones.

In that environment, a problem caused by an inaccurately translated label, a mistranslated IFU, or errors in the translation of patient safety documentation can cost months of rework and push your CE mark timeline out significantly. The same applies to the translation of patient information leaflets (a requirement in every EU member state that is frequently underestimated in scope and complexity).

The problem is compounded when medical device manufacturers use general-purpose vendors who aren't equipped to deliver regulatory compliance translations that meet MDR Annex I essential requirements.

What medical device manufacturers need is a translation partner that can supply:

• Native translators with European regulatory experience in EU MDR technical documentation to avoid inaccurate translations
• ISO 9001-certified quality management systems that map to the standards regulators expect
• Independent linguistic reviews and back translations to ensure correctness
• Certificates of translation that can be submitted directly to Notified Bodies

How SimulTrans solves this problem:

With over 40 years of experience, we have worked on hundreds of medical device projects and maintain ISO 9001 and ISO 17100 certifications. Every translation is backed by a quality process built specifically for the regulatory demands of the medical device industry. We also provide signed certificates of translation and back-translation services to verify accuracy before submission.

2. Updates and Changes Generate More Work

Medical devices don't stay static.  Diagnostic software updates, design modifications, changes to IFUs, and post-market surveillance findings all trigger updates. For a device sold in 20 or 30 countries, a single change to the IFU or labeling can mean 20 or 30 separate translation updates. Each one needs to go through a quality review before it can be used in the market.

Many medical device manufacturers approach this reactively, re-translating entire documents each time something changes. That approach is both expensive and slow. It's also unnecessary.

What medical device manufacturers need is a translation partner that can:

• Reuse previously approved translations automatically

• Translate and review (and charge) only new or changed content 

• Manage terminology (bilingual glossaries) to ensure consistency across all document versions

How SimulTrans solves this problem:

SimulTrans uses translation memory technology to ensure that translations are reused and that manufacturers never pay to translate the same content twice. When a document is updated, only the changed segments are sent for translation and review.  Approved terminology is uploaded to the Translation Management System, locked in, and applied consistently across all projects. This matters enormously when reliable medical translations are required at every stage of a regulatory audit trail. The result is faster turnaround on updates, lower per-project costs, and an auditable translation record across the entire translation lifecycle.

3. Lack of Specialization Creates Risk

Expanding into Japan, China, Brazil, or the Middle East means navigating regulatory frameworks that have very different documentation requirements from the FDA or EU MDR. Many of these agencies require not just translated labeling, but clinical trial document translation, regulatory submissions, and quality management system documentation. They also require professional translation of the diagnostic software.

This is where non-specialized translation vendors create real risk. A vendor without medical device experience may produce translations that are linguistically correct but technically wrong. For instance, using the wrong anatomical terminology, mistranslating a performance specification, or failing to adapt the software so it displays correctly for languages written right-to-left (like Arabic, Persian, or Hebrew). Any mistranslation can be fatal for patients and cause a compliance risk.

What medical device manufacturers need is a translation partner that can:

• Understand the requirements of the specific regulatory bodies in each target market

• Localize and test the software so it will work in different languages

• Deliver manuals that meet country-specific regulatory guidelines

How SimulTrans solves this problem:

SimulTrans supports medical device market expansions across many languages. Project managers with deep experience work directly with manufacturer regulatory teams to translate 510(k) submissions for the FDA in the USA,  PMDA submissions for Japan's market, or technical dossiers for ANVISA in Brazil.  Software localization engineers work on multilingual projects simultaneously to ensure software functions correctly in each language. Multilingual desktop publishers can create multilingual IFUs for each region.

Why Specialized Medical Device Translation Matters

Regulatory compliance, product lifecycle documentation, and international market expansion all depend on translation that is accurate, consistent, and delivered on time. Medical device translation is not general content work.  It sits at the intersection of regulatory compliance, patient safety, and product performance.

SimulTrans focuses specifically on medical device content, helping medical device companies reduce approval risk, protect users, and maintain confidence across global markets.

If translation bottlenecks are affecting your regulatory timelines, your labeling update cycles, or your international expansion plans, it's worth a conversation. Set up a meeting now.